Shares of Depomed (DEPO) get clobbered in the post trading session after the company says...

|About: Depomed Inc. (DEPO)|By:, SA News Editor

Shares of Depomed (DEPO) get clobbered in the post trading session after the company says top-line results from its Phase 3 trial evaluating the efficacy and safety of Serada, a drug for menopausal hot flashes, missed on a key secondary endpoint evaluation. Shares -24% AH.